Zoetis(ZTS) ZACKS·2025-04-29 15:06Core Viewpoint - The market anticipates Zoetis (ZTS) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus EPS estimate of $1.40, reflecting a 1.5% increase from the previous year [1][3]. Earnings Expectations - The expected revenue for Zoetis is $2.19 billion, indicating no change from the year-ago quarter [3]. - The stock may experience upward movement if the actual earnings exceed expectations, while a miss could lead to a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.23% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Zoetis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.15% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [7][8]. - Zoetis currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Zoetis had an earnings surprise of +2.19%, reporting $1.40 per share against an expectation of $1.37 [12]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [13]. Industry Comparison - Neurocrine Biosciences (NBIX), another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.42 per share, with revenues projected at $569.46 million, reflecting a 10.5% increase from the previous year [17]. - Neurocrine's consensus EPS estimate has been revised down by 5.2% over the last 30 days, resulting in an Earnings ESP of -37.31% [18].